Document Detail


Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry.
MedLine Citation:
PMID:  20566954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Optimal treatment strategies for restenosis of sirolimus-eluting stents (SES) have not been adequately addressed yet. METHODS AND RESULTS: During the 3-year follow-up of 12 824 patients enrolled in the j-Cypher registry, 1456 lesions in 1298 patients underwent target-lesion revascularization (TLR). Excluding 362 lesions undergoing TLR for stent thrombosis or TLR using treatment modalities other than SES or balloon angioplasty (BA), 1094 lesions with SES-associated restenosis in 990 patients treated with either SES (537 lesions) or BA (557 lesions) constituted the study population for the analysis of recurrent TLR and stent thrombosis after the first TLR. Excluding 24 patients with both SES- and BA-treated lesions, 966 patients constituted the analysis set for the mortality outcome. Cumulative incidence of recurrent TLR in the SES-treated restenosis lesions was significantly lower than that in the BA-treated restenosis lesions (23.8% versus 37.7% at 2 years after the first TLR; P<0.0001). Among 33 baseline variables evaluated, only hemodialysis was identified to be the independent risk factor for recurrent TLR by a multivariable logistic regression analysis. After adjusting for confounders, repeated SES implantation was associated with a strong treatment effect in preventing recurrent TLR over BA (odds ratio, 0.44; 95% confidence interval, 0.32 to 0.61; P<0.0001). The 2-year mortality and stent thrombosis rates between the SES- and the BA-treated groups were 10.4% versus 10.8% (P=0.4) and 0.6% versus 0.6%, respectively. CONCLUSIONS: Repeated implantation of SES for SES-associated restenosis is more effective in preventing recurrent TLR than treatment with BA, without evidence of safety concerns.
Authors:
Mitsuru Abe; Takeshi Kimura; Takeshi Morimoto; Takuya Taniguchi; Futoshi Yamanaka; Kazuhiro Nakao; Nobuhito Yagi; Nobuaki Kokubu; Yoichiro Kasahara; Yu Kataoka; Yoritaka Otsuka; Atsushi Kawamura; Shunichi Miyazaki; Koichi Nakao; Kenji Horiuchi; Akira Ito; Hiroshi Hoshizaki; Ren Kawaguchi; Manabu Setoguchi; Tsukasa Inada; Koichi Kishi; Hiroki Sakamoto; Nobuyuki Morioka; Masao Imai; Hiroki Shiomi; Hiroshi Nonogi; Kazuaki Mitsudo;
Related Documents :
24579804 - Dorsal onlay urethroplasty using buccal mucosa graft versus penile skin flap for manage...
16326374 - Comparison of a centered 32p source wire system with a noncentered 90sr/y brachytherapy...
12754534 - Door to needle time in administering thrombolytic therapy for acute myocardial infarction.
7572574 - Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type...
22974574 - Nail-fold excision for the treatment of ingrown toenail in children.
10795864 - Predictors of improvement in fev1 (forced expiratory volume in 1s) after lung volume re...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-06-21
Journal Detail:
Title:  Circulation     Volume:  122     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-07     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  42-51     Citation Subset:  AIM; IM    
Affiliation:
National Cardiovascular Center, Suita, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / epidemiology
Aged
Aged, 80 and over
Angioplasty, Balloon / adverse effects,  methods
Coronary Angiography
Coronary Artery Bypass / statistics & numerical data
Coronary Restenosis / drug therapy,  epidemiology,  surgery*
Drug-Eluting Stents
Female
Follow-Up Studies
Graft Occlusion, Vascular / epidemiology
Humans
Japan
Male
Middle Aged
Myocardial Revascularization / methods*
Prospective Studies
Recurrence / prevention & control
Registries
Renal Dialysis / adverse effects
Risk Factors
Sirolimus / therapeutic use*
Chemical
Reg. No./Substance:
53123-88-9/Sirolimus
Comments/Corrections
Comment In:
Circulation. 2010 Jul 6;122(1):5-7   [PMID:  20566948 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. A European...
Next Document:  Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients Wi...